Wednesday - January 14, 2026
Johnson & Johnson Elevates Leadership in Depression With New Data at 2026 American College of Neuropsychopharmacology Annual Meeting
January 14, 2026
RARITAN, New Jersey, Jan. 14 -- Johnson and Johnson Innovative Medicine issued the following news release:

* * *

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

New CAPLYTA(R) (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented

SPRAVATO(R) (esketamine) effects on anhedonia . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products